Abstract Study Objective Observational studies assessing direct oral anticoagulant (DOACs)
dosage in atrial fibrillation (AF) reported that a lower proportion of patients received high …

Reduced-dose apixaban is recommended in patients fulfilling 2 of 3 criteria: age≥ 80 years,
body weight≤ 60 kg, and serum creatinine≥ 1.5 mg/dL. However, patient weight is often not …

The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major
bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to …

Direct Oral Anticoagulants (DOACs) require dose adjustment based on specific patient
characteristics, making them prone to incorrect dosing. The current study aimed to evaluate …

In randomized trials comparing apixaban with warfarin or aspirin for stroke prevention in
atrial fibrillation, patients received a reduced dose of 2.5 mg twice daily (BID) if they met at …

Background Low-dose direct oral anticoagulant (DOAC) use is quite prevalent in clinical
practice, but evidence of its effectiveness and safety compared with high-dose DOAC in …

Highlights•Direct oral anticoagulants did not increase stroke or systemic embolism event
rate.•Direct oral anticoagulants had lower major bleeding rate than warfarin.•Direct oral …

Background Data on the relationship between body mass index (BMI), thromboembolic
events (TEE) and bleeding in patients with atrial fibrillation (AF) are controversial, and further …

Background Inappropriate doses of direct oral anticoagulants (DOACs) are often prescribed.
This study evaluated the prevalence, outcomes, and predictors of the prescription of …

East Asians are reportedly at high risk of anticoagulant-related bleeding; therefore, some
physicians prefer to prescribe low-dose direct oral anticoagulants (DOACs). Little is known …